Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

67.39 -0.20 (-0.30%)
Streaming Delayed Price Updated: 11:21 AM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 712,632
Open 67.80
Bid (Size) 67.37 (5)
Ask (Size) 67.39 (3)
Prev. Close 67.59
Today's Range 67.23 - 67.91
52wk Range 61.24 - 87.67
Shares Outstanding N/A
Dividend Yield 3.12%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results. 
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
From AstraZeneca
Via Business Wire

Performance

YTD
+2.3%
+2.3%
1 Month
-10.1%
-10.1%
3 Month
-0.8%
-0.8%
6 Month
-13.0%
-13.0%
1 Year
-3.9%
-3.9%

More News

Read More
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political
Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now
Via The Motley Fool
Topics Economy Government Stocks
Exposures COVID-19 Economy Interest Rates
Why the quality investor may take a look at ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN).
Via Chartmill
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Via Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
3 No-Brainer Growth Stocks to Buy for Less Than $100
Via The Motley Fool
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
Via Benzinga
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Political Tariff
Peering Into AstraZeneca's Recent Short Interest
Via Benzinga
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
Via Benzinga
Exposures Product Safety
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
Via Investor's Business Daily
​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
Competitive Analysis In The ATTR-CM Field
Via Talk Markets
Topics Stocks / Equities
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Via Benzinga
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
Via FinancialNewsMedia
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
Via Benzinga
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
From AstraZeneca
Via Business Wire
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead
Via The Motley Fool

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 67.39
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 04/21/25 11:21 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.